R&D Experimental Services: COVID-19 Drug Development

In response to the COVID-19 pandemic, R&D service companies have created research models and tools adapted to SARS-CoV-2: in vitro assays on Vero E6, Caco-2, Calu-3 models or ex vivo on epithelial airway explants (HAE), in vivo tests on hACE2 humanized mice or on golden hamster, with the use of original, alpha, delta or omicron variants, for the development of COVID-19 drugs, vaccines, validation of immunological, PCR or side-flow diagnostic kits, measurement of virucidal effects of materials directly on SARS-CoV-2.

Finding the right laboratory with the set of competencies required for a COVID-19 project, however, can be difficult.

 This is why Labtoo developed a tailor-made service to support Labs, Biotechs, Medtech, and Pharma companies in their SARS-CoV-2 research programs.

Labtoo can look for any type of SARS-CoV-2 experimental services,  for the development of new drugs and the development of diagnostics assays. We work with a large international network of laboratories and service companies to provide the largest options for your project.

What is included in our services?

Our team will handle your R&D service management from the beginning to the end

Perform a feasibility study by looking for existing expertise available within the network of partners


Set up a study protocol, financial quotation and preparing contracts with lab partners


Implement the study plan into a schedule, collect all needed materials and reagents and execute the service

Do you need more information about our experimental services?

favicon large un peu plus-1